Stereoselective determination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 583-590

  Kingbäck, Maria ^a   Josefsson, Martin ^b   Karlsson, Louise ^a   Ahlner, Johan ^a,b   Bengtsson, Finn ^a   Kugelberg, Fredrik C ^a,b   Carlsson, Björn ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b National Board of Forensic Medicine   (Sweden)

Author keywords

Enantiomers; Human; LC ESI MS MS; Metabolites; Venlafaxine

Indexed keywords

DESVENLAFAXINE; DRUG METABOLITE; MEXILETINE; N DESMETHYLVENLAFAXINE; N,O DIDESMETHYLVENLAFAXINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; AUTOPSY; BLOOD; BLOOD SAMPLING; DRUG DETERMINATION; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; STEREOCHEMISTRY;

CHROMATOGRAPHY, LIQUID; CYCLOHEXANOLS; DRUG STABILITY; HUMANS; SEROTONIN UPTAKE INHIBITORS; SOLID PHASE EXTRACTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM;

EID: 77954861741     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.03.043     Document Type: Article

References (32)

1. Hutt A.J. Chirality and pharmacokinetics: an area of neglected dimensionality?. Drug Metabol. Drug Interact. 2007, 22:79-112.
2. Lu H. Stereoselectivity in drug metabolism. Expert Opin. Drug Metab. Toxicol. 2007, 3:149-158.
3. Brocks D.R. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharm. Drug Dispos. 2006, 27:387-406.
4. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E., Nielsen S.T., Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 1986, 35:4493-4497.
5. Holliday S.M., Benfield P., Venlafaxine A review of its pharmacology and therapeutic potential in depression. Drugs 1995, 49(2):280-294.
6. Otton S.V., Ball S.E., Cheung S.W., Inaba T., Rudolph R.L., Sellers E.M. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br. J. Clin. Pharmacol. 1996, 41:149-156.
7. Fogelman S.M., Schmider J., Venkatakrishnan K., von Moltke L.L., Harmatz J.S., Shader R.I., Greenblatt D.J. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999, 20:480-490.
8. Eap C.B., Lessard E., Baumann P., Brawand-Amey M., Yessine M.A., O'Hara G., Turgeon J. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 2003, 13:39-47.
9. Matoga M., Pehourcq F., Titier K., Dumora F., Jarry C. Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma Application to management of acute intoxications. J. Chromatogr. B Biomed. Sci. Appl. 2001, 760:213-218.
10. Makhija S.N., Vavia P.R. Stability indicating LC method for the estimation of venlafaxine in pharmaceutical formulations. J. Pharm. Biomed. Anal. 2002, 28:1055-1059.
11. Mandrioli R., Mercolini L., Cesta R., Fanali S., Amore M., Raggi M.A. Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 856:88-94.
12. Hicks D.R., Wolaniuk D., Russell A., Cavanaugh N., Kraml M. A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids. Ther. Drug Monit. 1994, 16:100-107.
13. Wang C.P., Howell S.R., Scatina J., Sisenwine S.F. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality 1992, 4:84-90.
14. Vu R.L., Helmeste D., Albers L., Reist C. Rapid determination of venlafaxine and O-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorimetric detection. J. Chromatogr. B Biomed. Sci. Appl. 1997, 703:195-201.
15. Waschgler R., Moll W., Konig P., Conca A. Quantification of venlafaxine and O-desmethylvenlafaxine in human serum using HPLC analysis. Int. J. Clin. Pharmacol. Ther. 2004, 42:724-728.
16. Qin X.Y., Meng J., Li X.Y., Zhou J., Sun X.L., Wen A.D. Determination of venlafaxine in human plasma by high-performance liquid chromatography using cloud-point extraction and spectrofluorimetric detection. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 2008, 872:38-42.
17. Wei Z., Bing-Ren X., Cai-Yun W. Liquid chromatography-mass spectrometry method for the determination of venlafaxine in human plasma and application to a pharmacokinetic study. Biomed. Chromatogr. 2007, 21:266-272.
18. Liu W., Wang F., Li H.D. Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in human plasma by HPLC-ESI/MS using a vancomycin chiral column. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 850:183-189.
19. Rudaz S., Stella C., Balant-Gorgia A.E., Fanali S., Veuthey J.L. Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in clinical samples by capillary electrophoresis using charged cyclodextrins. J. Pharm. Biomed. Anal. 2000, 23:107-115.
20. Fanali S., Rudaz S., Veuthey J.L., Desiderio C. Use of vancomycin silica stationary phase in packed capillary electrochromatography II. Enantiomer separation of venlafaxine and O-desmethylvenlafaxine in human plasma. J. Chromatogr. A 2001, 919:195-203.
21. Armstrong D.W., Rundlett K.L., Chen J.R. Evaluation of the macrocyclic antibiotic vancomycin as a chiral selector for capillary electrophoresis. Chirality 1994, 6:496-509.
22. Frahnert C., Rao M.L., Grasmader K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 794:35-47.
23. Bhatt J., Jangid A., Venkatesh G., Subbaiah G., Singh S. Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for simultaneous determination of venlafaxine and its active metabolite O-desmethyl venlafaxine in human plasma. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 2005, 829:75-81.
24. Wille S.M., Maudens K.E., Van Peteghem C.H., Lambert W.E. Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis. J. Chromatogr. A 2005, 1098:19-29.
25. Theron H.B., van der Merwe M.J., Swart K.J., van der Westhuizen J.H. Employing atmospheric pressure photoionization in liquid chromatography/tandem mass spectrometry to minimize ion suppression and matrix effects for the quantification of venlafaxine and O-desmethylvenlafaxine. Rapid Commun. Mass Spectrom. 2007, 21:1680-1686.
26. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
27. Desai M.J., Armstrong D.W. Transforming chiral liquid chromatography methodologies into more sensitive liquid chromatography-electrospray ionization mass spectrometry without losing enantioselectivity. J. Chromatogr. A 2004, 1035:203-210.
28. Meyer V. Accuracy in the chromatographic determination of extreme enantiomeric ratios: A critical reflection. Chirality 1995, 7:567-571.
29. Carlsson B., Olsson G., Reis M., Walinder J., Nordin C., Lundmark J., et al. Enantioselective analysis of citalopram and metabolites in adolescents. Ther. Drug Monit. 2001, 23:658-664.
30. Holmgren P., Carlsson B., Zackrisson A.L., Lindblom B., Dahl M.L., Scordo M.G., et al. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19. J. Anal. Toxicol. 2004, 28:94-104.
31. Kronstrand R., Josefsson M. Quantification using LC-MS. Applications of LC-MS in Toxicology 2006, 43-70. Pharmaceutical Press. A. Polettini (Ed.).
32. Reis M., Aamo T., Ahlner J., Druid H. Reference concentrations of antidepressants: a compilation of postmortem and therapeutic levels. J. Anal. Toxicol. 2007, 31:254-264.